

Isabel T Rubio

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7197944/publications.pdf>

Version: 2024-02-01

138
papers

7,533
citations

109321

35
h-index

56724

83
g-index

152
all docs

152
docs citations

152
times ranked

9102
citing authors

#	ARTICLE	IF	CITATIONS
1	Health-Related Quality of Life After Nipple-Sparing Mastectomy: Results From the INSPIRE Registry. <i>Annals of Surgical Oncology</i> , 2022, 29, 1722-1734.	1.5	3
2	ASO Visual Abstract: Health-Related Quality of Life After Nipple-Sparing Mastectomy: Results from the INSPIRE Registry. <i>Annals of Surgical Oncology</i> , 2022, 29, 1735-1736.	1.5	0
3	Four-fraction ultra-accelerated minimal breast irradiation in early breast cancer: The initial feasibility results of an institutional experience. <i>Brachytherapy</i> , 2022, 21, 475-486.	0.5	6
4	Oncoplastic breast consortium recommendations for mastectomy and whole breast reconstruction in the setting of post-mastectomy radiation therapy. <i>Breast</i> , 2022, 63, 123-139.	2.2	22
5	Axillary surgery after neoadjuvant therapy in initially node-positive breast cancer: international EUBREAST survey. <i>British Journal of Surgery</i> , 2022, 109, 857-863.	0.3	22
6	Leveraging the increased rates of pathologic complete response after neoadjuvant treatment in breast cancer to de-escalate surgical treatments. <i>Journal of Surgical Oncology</i> , 2021, 123, 71-79.	1.7	11
7	Breast conservation and axillary management after primary systemic therapy in patients with early-stage breast cancer: the Lucerne toolbox. <i>Lancet Oncology</i> , The, 2021, 22, e18-e28.	10.7	49
8	Local Treatment of Triple-Negative Breast Cancer. <i>Cancer Journal (Sudbury, Mass)</i> , 2021, 27, 32-40.	2.0	2
9	Surgical Management of the Axilla in Clinically Node-Positive Breast Cancer Patients Converting to Clinical Node Negativity through Neoadjuvant Chemotherapy: Current Status, Knowledge Gaps, and Rationale for the EUBREAST-03 AXSANA Study. <i>Cancers</i> , 2021, 13, 1565.	3.7	85
10	70-gene signature as an aid for treatment decisions in early breast cancer: updated results of the phase 3 randomised MINDACT trial with an exploratory analysis by age. <i>Lancet Oncology</i> , The, 2021, 22, 476-488.	10.7	179
11	The temporal mutational and immune tumour microenvironment remodelling of HER2-negative primary breast cancers. <i>Npj Breast Cancer</i> , 2021, 7, 73.	5.2	2
12	Evaluation of multiple transcriptomic gene risk signatures in male breast cancer. <i>Npj Breast Cancer</i> , 2021, 7, 98.	5.2	4
13	The ESSO core curriculum committee update on surgical oncology. <i>European Journal of Surgical Oncology</i> , 2021, 47, e1-e30.	1.0	6
14	Neoadjuvant eribulin in HER2-negative early-stage breast cancer (SOLTI-1007-NeoEribulin): a multicenter, two-cohort, non-randomized phase II trial. <i>Npj Breast Cancer</i> , 2021, 7, 145.	5.2	9
15	Neoadjuvant approach in patients with early breast cancer: patient assessment, staging, and planning. <i>Breast</i> , 2021, , .	2.2	3
16	Breast and axillary surgery in malignant breast disease: a review focused on literature of 2018 and 2019. <i>Current Opinion in Obstetrics and Gynecology</i> , 2020, 32, 91-99.	2.0	8
17	Missed opportunities and challenges for surgical breast cancer research in the era of personalized cancer treatment. <i>European Journal of Surgical Oncology</i> , 2020, 46, 501-503.	1.0	1
18	Axillary staging based on molecular analysis: Results of the B-CLOSER-II study. <i>Pathology Research and Practice</i> , 2020, 216, 153197.	2.3	4

#	ARTICLE	IF	CITATIONS
19	The requirements of a specialist breast centre. Breast, 2020, 51, 65-84.	2.2	111
20	A randomized study comparing different doses of superparamagnetic iron oxide tracer for sentinel lymph node biopsy in breast cancer: The SUNRISE study. European Journal of Surgical Oncology, 2020, 46, 2195-2201.	1.0	22
21	Theoretical and practical knowledge curriculum for European Breast Surgeons. European Journal of Surgical Oncology, 2020, 46, 717-736.	1.0	12
22	Standard Anthracycline Based Versus Docetaxel-Capecitabine in Early High Clinical and/or Genomic Risk Breast Cancer in the EORTC 10041/BIG 3-04 MINDACT Phase III Trial. Journal of Clinical Oncology, 2020, 38, 1186-1197.	1.6	10
23	Should breast reconstruction and breast oncoplastic procedures be performed during the coronavirus pandemic?. Ecanermediscience, 2020, 14, 1041.	1.1	9
24	Minimally invasive tumor bed implant (MITBI) and peri-operative high-dose-rate brachytherapy (PHDRBT) for accelerated minimal breast irradiation (AMBI) or anticipated boost (A-PHDRBT-boost) in breast-conserving surgery for ductal carcinoma in situ. Journal of Contemporary Brachytherapy, 2020, 12, 521-532.	0.9	3
25	Abstract P4-10-03: The genomic landscape of male breast cancers using the oncomine comprehensive assay for actionable mutations. , 2020, , .		0
26	European Guidelines on the Organisation of Breast Centres and Voluntary Certification Processes. Breast Care, 2019, 14, 359-365.	1.4	4
27	Education and Training in Breast Cancer Surgery in Europe. Breast Care, 2019, 14, 366-372.	1.4	7
28	Transforming Breast Cancer Together: European elections manifesto 2019 seizing the opportunities for breast cancer patients. Breast, 2019, 48, 54-57.	2.2	2
29	EUSOMA position regarding breast implant associated anaplastic large cell lymphoma (BIA-ALCL) and the use of textured implants. Breast, 2019, 44, 90-93.	2.2	25
30	Learning curves in intraoperative ultrasound guided surgery in breast cancer based on complete breast cancer excision and no need for second surgeries. European Journal of Surgical Oncology, 2019, 45, 578-583.	1.0	15
31	Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology, 2019, 30, 1194-1220.	1.2	1,241
32	European Society of Surgical Oncology's strategy for clinical research: Paving the way for a culture of research in cancer surgery. European Journal of Surgical Oncology, 2019, 45, 1515-1519.	1.0	2
33	About the French prohibition of textured breast implants: is it justified or over-cautious? The EUSOMA, ESSO/BRESSO position. Breast, 2019, 46, 95-96.	2.2	2
34	Neoadjuvant Management of Early Breast Cancer: A Clinical and Investigational Position Statement. Oncologist, 2019, 24, 603-611.	3.7	43
35	A gap analysis of opportunities and priorities for breast surgical research. Lancet Oncology, The, 2019, 20, e1.	10.7	1
36	Variability in breast cancer surgery training across Europe: An ESSO-EUSOMA international survey. European Journal of Surgical Oncology, 2019, 45, 567-572.	1.0	22

#	ARTICLE	IF	CITATIONS
37	Percutaneous ultrasound-guided vacuum-assisted excision of benign breast lesions: A learning curve to assess outcomes. British Journal of Radiology, 2019, 92, 20180626.	2.2	16
38	Abstract P6-19-01: Evaluation of multiple transcriptomic gene risk signatures in male breast cancer. , 2019,, .		0
39	Abstract P3-03-15: Patient reported outcomes in women undergoing sentinel lymph node biopsy in the SUNRISE randomized trial evaluating different doses of superparamagnetic iron oxide. , 2019,, .		0
40	Breast and axillary conservative surgery after neoadjuvant treatment in HER 2 positive breast cancer patients: The time is now. European Journal of Cancer, 2018, 92, S13-S14.	2.8	0
41	Routine nodal radiation therapy may be avoided in Z0011 eligible breast cancer patients. It is time to reduce morbidity from axillary treatment. European Journal of Cancer, 2018, 92, S59.	2.8	0
42	RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer. Annals of Oncology, 2018, 29, 1203-1210.	1.2	280
43	A European, Observational Study of Endocrine Therapy Administration in Patients With an Initial Diagnosis of Hormone Receptor-Positive Advanced Breast Cancer. Clinical Breast Cancer, 2018, 18, e613-e619.	2.4	9
44	Axillary Reverse Mapping: ARM. , 2018, , 303-312.		0
45	Variations in the opinion of breast surgeons and radiation oncologist regarding indications for radiation therapy after NSM: The need for prospective studies. European Journal of Surgical Oncology, 2018, 44, 3-4.	1.0	0
46	Characterization of male breast cancer: results of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program. Annals of Oncology, 2018, 29, 405-417.	1.2	246
47	Risk factors for locoregional disease recurrence after breast-conserving therapy in patients with breast cancer treated with neoadjuvant chemotherapy: An international collaboration and individual patient meta-analysis. Cancer, 2018, 124, 2923-2930.	4.1	39
48	Intraoperative Ultrasound-Guided Excision of Axillary Clip in Patients with Node-Positive Breast Cancer Treated with Neoadjuvant Therapy (ILINA Trial). Annals of Surgical Oncology, 2018, 25, 784-791.	1.5	101
49	Breast-conserving surgery following neoadjuvant therapy-a systematic review on surgical outcomes. Breast Cancer Research and Treatment, 2018, 168, 1-12.	2.5	55
50	p95HER2- α T cell bispecific antibody for breast cancer treatment. Science Translational Medicine, 2018, 10, .	12.4	59
51	ASO Author Reflections: Moving Forward De-escalation of Axillary Surgery After Neoadjuvant Treatment in Breast Cancer. Annals of Surgical Oncology, 2018, 25, 638-639.	1.5	9
52	A γ RAD51 assay feasible in routine tumor samples calls γ PARP inhibitor response beyond γ BRCA mutation. EMBO Molecular Medicine, 2018, 10, .	6.9	169
53	Oncoplastic Breast Consortium consensus conference on nipple-sparing mastectomy. Breast Cancer Research and Treatment, 2018, 172, 523-537.	2.5	84
54	Changes in Ki 67 expression after neoadjuvant therapy in HER2 positive breast cancer patients treated with trastuzumab and pertuzumab are independent predictors of response and prognosis. European Journal of Cancer, 2018, 92, S98.	2.8	0

#	ARTICLE	IF	CITATIONS
55	Perspectives on preoperative systemic treatment and breast conservative surgery: One step forward or two steps back?. Breast, 2018, 41, 133-135.	2.2	8
56	Role of total tumour load of sentinel lymph node on survival in early breast cancer patients. Breast, 2017, 33, 8-13.	2.2	34
57	Breast implant associated anaplastic large cell lymphoma: Impact and implications. European Journal of Surgical Oncology, 2017, 43, 1383-1384.	1.0	3
58	Global Forum of Cancer Surgeons: Declaration of Intent. Annals of Surgical Oncology, 2017, 24, 2429-2431.	1.5	13
59	Intraoperative assessment of sentinel lymph node by one-step nucleic acid amplification in breast cancer patients after neoadjuvant treatment reduces the need for a second surgery for axillary lymph node dissection. Breast, 2017, 31, 40-45.	2.2	16
60	Abstract P1-09-09: Efficacy and gene expression results from SOLT11007 NEOERIBULIN phase II clinical trial in HER2-negative early breast cancer. , 2017, , .		3
61	Standard anthracycline-based vs. docetaxel-capecitabine in early breast cancer: Results from the chemotherapy randomization (R-C) of EORTC 10041/ BIG 3-04 MINDACT phase III trial.. Journal of Clinical Oncology, 2017, 35, 516-516.	1.6	3
62	Abstract P3-13-23: Predicting residual disease in breast conservative surgery after neoadjuvant treatments in breast cancer patients using the margin index tool. , 2017, , .		0
63	Intraoperative ultrasound guided breast surgery: paving the way for personalized surgery. Gland Surgery, 2016, 5, 366-368.	1.1	7
64	The cancer stem-cell signaling network and resistance to therapy. Cancer Treatment Reviews, 2016, 49, 25-36.	7.7	122
65	Different Prognostic Implications of Residual Disease After Neoadjuvant Treatment: Impact of Ki 67 and Site of Response. Annals of Surgical Oncology, 2016, 23, 3831-3837.	1.5	29
66	Lack of RAD51 foci formation enables the identification of PARP inhibitor sensitive breast tumors. European Journal of Cancer, 2016, 69, S122-S123.	2.8	0
67	70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer. New England Journal of Medicine, 2016, 375, 717-729.	27.0	1,427
68	Sentinel lymph node biopsy after neoadjuvant treatment in breast cancer: Work in progress. European Journal of Surgical Oncology, 2016, 42, 326-332.	1.0	25
69	Clinical utility of Axillary Reverse Mapping (ARM) in an era of changing perceptions concerning axillary surgery. European Journal of Surgical Oncology, 2016, 42, 585-587.	1.0	3
70	Margins in breast conserving surgery: A practice-changing process. European Journal of Surgical Oncology, 2016, 42, 631-640.	1.0	20
71	Intraoperative Ultrasound-Guided Lumpectomy Versus Mammographic Wire Localization for Breast Cancer Patients After Neoadjuvant Treatment. Annals of Surgical Oncology, 2016, 23, 38-43.	1.5	50
72	Abstract CT039: Primary analysis of the EORTC 10041/ BIG 3-04 MINDACT study: a prospective, randomized study evaluating the clinical utility of the 70-gene signature (MammaPrint) combined with common clinical-pathological criteria for selection of patients for adjuvant chemotherapy in breast cancer with 0 to 3 positive nodes. , 2016, , .		16

#	ARTICLE	IF	CITATIONS
73	Prognostic and therapeutic implications of fibroblast growth factor receptors (FGFRs) 1 and 2 gene amplifications in patients (pts) with advanced breast cancer (ABC).. Journal of Clinical Oncology, 2016, 34, 537-537.	1.6	2
74	Modeling anti-IL-6 therapy using breast cancer patient-derived xenografts. Oncotarget, 2016, 7, 67956-67965.	1.8	4
75	Abstract P3-01-04: Improved sentinel lymph node detection with the use of superparamagnetic iron oxide tracer after neoadjuvant treatment in breast cancer patients. , 2016, , .		0
76	Analysis of total tumor load of sentinel lymph node as a prognostic factor in patients with early breast cancer.. Journal of Clinical Oncology, 2016, 34, 1042-1042.	1.6	0
77	Sentinel lymph node metastasis after neoadjuvant treatment in breast cancer: Any size matters?. World Journal of Clinical Oncology, 2015, 6, 202.	2.3	9
78	Effect of Cellular Senescence on the Growth of HER2-Positive Breast Cancers. Journal of the National Cancer Institute, 2015, 107, djv020-djv020.	6.3	32
79	Gene expressionâ€based classifications of fibroadenomas and phyllodes tumours of the breast. Molecular Oncology, 2015, 9, 1081-1090.	4.6	39
80	The superparamagnetic iron oxide is equivalent to the Tc99 radiotracer method for identifying the sentinel lymph node in breast cancer. European Journal of Surgical Oncology, 2015, 41, 46-51.	1.0	104
81	Surgery improves survival in elderly with breast cancer. A study of 465 patients in a single institution. European Journal of Surgical Oncology, 2015, 41, 635-640.	1.0	20
82	Surgical treatment of nonpalpable primary invasive and in situ breast cancer. Nature Reviews Clinical Oncology, 2015, 12, 645-663.	27.6	47
83	Abstract S6-05: Characterization of male breast cancer: First results of the EORTC10085/TBCRC/BIG/NABCG International Male BC Program. , 2015, , .		20
84	Patterns of HER2 Gene Amplification and Response to Anti-HER2 Therapies. PLoS ONE, 2015, 10, e0129876.	2.5	45
85	Abstract P2-01-17: Total tumoral load as a prediction tool of non-sentinel node metastases in patients with early breast cancer and positive sentinel lymph node assesed by OSNA. , 2015, , .		0
86	Breast conservative surgery in breast cancer: Simple can be harder than complex. Journal of Surgical Oncology, 2014, 110, 1-1.	1.7	8
87	Factors affecting surgical management following neoadjuvant therapy in patients with primary HER2-positive breast cancer: results from the NeoALTTO phase III trial. Annals of Oncology, 2014, 25, 910-911.	1.2	7
88	Effect of p95HER2/611CTF on the Response to Trastuzumab and Chemotherapy. Journal of the National Cancer Institute, 2014, 106, .	6.3	36
89	Breast-Conservative Surgery Followed by Radiofrequency Ablation of Margins Decreases the Need for a Second Surgical Procedure for Close or Positive Margins. Clinical Breast Cancer, 2014, 14, 346-351.	2.4	9
90	Detection of sentinel lymph node in breast cancer recurrence may change adjuvant treatment decision in patients with breast cancer recurrence and previous axillary surgery. Breast, 2014, 23, 460-465.	2.2	12

#	ARTICLE	IF	CITATIONS
91	Changes in Breast Cancer Reports after Pathology Second Opinion. Breast Journal, 2014, 20, 295-301.	1.0	17
92	306: Chemotherapy sensitizes p95HER2-positive breast cancers to trastuzumab. European Journal of Cancer, 2014, 50, S72-S73.	2.8	0
93	Nomogram including the total tumoral load in the sentinel nodes assessed by one-step nucleic acid amplification as a new factor for predicting nonsentinel lymph node metastasis in breast cancer patients. Breast Cancer Research and Treatment, 2014, 147, 371-380.	2.5	40
94	Positive sentinel lymph node: the evolution of axillary surgery and intraoperative assessment of sentinel lymph nodes. Breast Cancer Management, 2014, 3, 369-376.	0.2	0
95	Increased detection of sentinel nodes in breast cancer patients with the use of superparamagnetic iron oxide tracer.. Journal of Clinical Oncology, 2014, 32, 100-100.	1.6	3
96	Factors associated with surgical management following neoadjuvant therapy in patients with primary HER2-positive breast cancer: results from the NeoALTTO phase III trial. Annals of Oncology, 2013, 24, 1980-1985.	1.2	32
97	Intraoperative molecular analysis of total tumor load in sentinel lymph node: a new predictor of axillary status in early breast cancer patients. Breast Cancer Research and Treatment, 2013, 139, 87-93.	2.5	101
98	Multidisciplinary approach to breast cancer diagnosed during pregnancy: Maternal and neonatal outcomes. Breast, 2013, 22, 515-519.	2.2	22
99	Surgery improves breast cancer-specific survival in octogenarians with early-stage breast cancer. International Journal of Surgery, 2013, 11, 554-557.	2.7	12
100	Prediction of non-sentinel lymph node metastasis in early breast cancer by assessing total tumoral load in the sentinel lymph node by molecular assay. European Journal of Surgical Oncology, 2013, 39, 766-773.	1.0	50
101	Management of the axilla in early breast cancer patients in the genomic era. Annals of Oncology, 2013, 24, 1163-1170.	1.2	9
102	Re: Time to Adjuvant Chemotherapy for Breast Cancer in National Comprehensive Cancer Network Institutions. Journal of the National Cancer Institute, 2013, 105, 1912-1912.	6.3	1
103	Oral Glutamine Reduces Radiation Morbidity in Breast Conservation Surgery. Journal of Parenteral and Enteral Nutrition, 2013, 37, 623-630.	2.6	21
104	Lymphatic mapping could not be impaired in the presence of breast carcinoma and coexisting small lymphocytic lymphoma. American Journal of Case Reports, 2013, 14, 322-325.	0.8	12
105	E9. Oncoplastic Surgery: increasing surgical options for breast cancer patients. European Journal of Cancer, 2012, 48, S20-S21.	2.8	0
106	PI3K Inhibition Impairs BRCA1/2 Expression and Sensitizes BRCA-Proficient Triple-Negative Breast Cancer to PARP Inhibition. Cancer Discovery, 2012, 2, 1036-1047.	9.4	507
107	The Discrepancy Between High Pathological Complete Response (PCR) Rate and Low Breast Conserving Surgery (BCS) Following Neoadjuvant Therapy: Analysis from the Neoaltto Trial (BIG 1-06). Annals of Oncology, 2012, 23, ix4.	1.2	1
108	Extensive nodal involvement increases the positivity of blue nodes in the axillary reverse mapping procedure in patients with breast cancer. Journal of Surgical Oncology, 2012, 106, 89-93.	1.7	29

#	ARTICLE	IF	CITATIONS
109	Pregnancy after treatment of breast cancer in young women does not adversely affect the prognosis. Breast, 2012, 21, 272-275.	2.2	21
110	Abstract 3746: PI3K inhibition sensitizes to PARP inhibitors in patient-derived xenograft models of triple negative breast cancer. , 2012, , .		1
111	Breast conservative surgery after neoadjuvant chemotherapy in breast cancer patients: Comparison of two tumor localization methods. European Journal of Surgical Oncology, 2011, 37, 1038-1043.	1.0	17
112	Electrothermal bipolar vessel sealing system in axillary dissection: A prospective randomized clinical study. International Journal of Surgery, 2011, 9, 636-640.	2.7	31
113	Breast Metastasis from Rhabdomyosarcoma of the Nasal Septum in a Pregnant Adult Woman. Breast Journal, 2011, 17, 420-421.	1.0	4
114	P3-07-45: Role of SPECT-CT in Detecting Sentinel Lymph Nodes in Patients with Ipsilateral Breast Cancer Recurrence and Previous Axillary Lymph Node Dissection.. , 2011, , .		0
115	P3-07-21: Sentinel Lymph Node Metastasis Are More Likely To Develop in Triple Positive Breast Cancer Patients without Compromising Disease Free Survival.. , 2011, , .		0
116	P3-07-11: Multicenter Comparative Study between One-Step Nucleic Acid Amplification (OSNA) Whole Node Assay and Standard Frozen Section Histology: Intraoperative Molecular Assay for Sentinel Lymph Node Metastases in Early Breast Cancer Can Avoid a Second Surgery.. Cancer Research, 2011, 71, P3-07-11-P3-07-11.	0.9	1
117	Intraoperative Assessment of Sentinel Lymph Nodes After Neoadjuvant Chemotherapy in Patients with Breast Cancer. Annals of Surgical Oncology, 2010, 17, 235-239.	1.5	35
118	Can we predict local recurrence in breast conserving surgery after neoadjuvant chemotherapy?. European Journal of Surgical Oncology, 2010, 36, 528-534.	1.0	23
119	Boosting the tumor bed from deep-seated tumors in early-stage breast cancer: A planning study between electron, photon, and proton beams. Radiotherapy and Oncology, 2010, 96, 192-198.	0.6	33
120	Abstract P5-14-14: Benefit of Metallic Marker for Tumor Localization in Breast Cancer Patients Treated with Breast Conservative Surgery after Neoadjuvant Treatment. Comparative Study of Tumor Localization Markers. , 2010, , .		0
121	Abstract P1-01-05: Clinical Significance of Tumor Burden in the Sentinel Nodes after Neoadjuvant Therapy Differs from Sentinel Nodes in the Adjuvant Setting and This May Influence the Management of the Axilla. , 2010, , .		0
122	Use of genome typing in breast cancer. Journal of Surgical Oncology, 2009, 99, 3-4.	1.7	0
123	Skin sparing mastectomy and immediate breast reconstruction: more indications with no increased in recurrences in breast cancer patients.. , 2009, , .		0
124	Removal of all radioactive sentinel nodes in breast cancer improves the detection of positive sentinel nodes. Clinical and Translational Oncology, 2008, 10, 347-350.	2.4	3
125	Positive sentinel lymph node: New controversies regarding axillary node dissection. Journal of Surgical Oncology, 2006, 93, 517-518.	1.7	2
126	Surgical use of breast ultrasound. Surgical Clinics of North America, 2003, 83, 771-788.	1.5	21

#	ARTICLE	IF	CITATIONS
127	Intraoperative touch preparation for sentinel lymph node biopsy: A 4-year experience. Annals of Surgical Oncology, 2002, 9, 333-339.	1.5	82
128	Intraoperative Touch Preparation for Sentinel Lymph Node Biopsy: A 4-Year Experience. Annals of Surgical Oncology, 2002, 9, 333-339.	1.5	6
129	Racial Differences in Breast Cancer Survival: The Effect of Residual Disease. Journal of Surgical Research, 2001, 100, 161-165.	1.6	14
130	Intraoperative localization after stereotactic breast biopsy without a needle. American Journal of Surgery, 2001, 182, 584-589.	1.8	37
131	Techniques of sentinel lymph node biopsy. Journal of Surgical Oncology, 2001, 20, 214-223.	1.4	18
132	Impact of multicentricity on clinical outcome in patients with T1-2, N0-1, M0 breast cancer. Annals of Surgical Oncology, 2000, 7, 581-587.	1.5	75
133	Role of Specimen Radiography in Patients Treated With Skin-Sparing Mastectomy for Ductal Carcinoma In Situ of the Breast. Annals of Surgical Oncology, 2000, 7, 544-548.	1.5	46
134	Intraoperative ultrasound-guided breast biopsy. American Journal of Surgery, 2000, 180, 419-423.	1.8	90
135	Subareolar Versus Peritumoral Injection for Location of the Sentinel Lymph Node. Annals of Surgery, 1999, 229, 860.	4.2	304
136	Use of touch preps for intraoperative diagnosis of sentinel lymph node metastases in breast cancer. Annals of Surgical Oncology, 1998, 5, 689-694.	1.5	157
137	Sentinel lymph node biopsy for staging breast cancer. American Journal of Surgery, 1998, 176, 532-537.	1.8	98
138	Effect of Glutamine on Methotrexate Efficacy and Toxicity. Annals of Surgery, 1998, 227, 772-780.	4.2	50